NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

非小細胞肺癌:全球治療藥物市場的預測和分析(至2029年)

Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029

出版商 GlobalData 商品編碼 980209
出版日期 內容資訊 英文 181 Pages
訂單完成後即時交付
價格
非小細胞肺癌:全球治療藥物市場的預測和分析(至2029年) Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029
出版日期: 2020年12月30日內容資訊: 英文 181 Pages
簡介

本報告分析了非小細胞肺癌(NSCLC)治療的全球市場,並提供了該疾病的概述和流行病學背景,流行趨勢的展望,臨床試驗的進展以及市場/臨床試驗。我們正在調查市場上的主要治療劑,當前市場未滿足的需求,主要公司的概況以及八個主要國家(美國,五個主要歐洲國家,日本和中國)的市場趨勢展望。

目錄

第1章目錄

第2章非小細胞肺癌(NSCLC):執行摘要

第3章簡介

第4章疾病概述

  • 病因與病理生理
  • 分類/分期系統

第5章流行病學

  • 疾病背景
  • 危險因素和併發症
  • 世界過去的趨勢
  • 預測方法
    • 使用的情報源
    • 預測的前提條件和方法
    • 已諮詢的非小細胞肺癌病例數
    • 諮詢過的NSCLC病例數:診斷時分階段
    • NSCLC諮詢次數:按組織類型
    • 診斷的非鱗狀上皮癌/鱗狀上皮癌病例數:突變數
    • NSCLC 5年患病率
  • 非小細胞肺癌(NSCLC)的流行病學預測(2019-2029)
    • 已諮詢的非小細胞肺癌病例數
    • 諮詢過的NSCLC病例數:按性別
    • NSCLC諮詢次數:按年齡
    • 諮詢過的NSCLC病例數:診斷時分階段
    • NSCLC諮詢次數:按組織類型
    • 診斷的非鱗狀上皮癌數目:通過突變基因組生物標誌物,EGFR,KRAS突變
    • 確診的鱗狀上皮癌病例數:按突變
    • NSCLC 5年患病率
  • 討論
    • 瞭解流行病學預測
    • 分析極限
    • 分析優勢

第6章疾病管理

  • 診斷和治療概述
  • 美國
  • 5個主要歐洲國家(5EU)
  • 日本
  • 中國

第7章競爭評估

  • 概述

第8章未滿足的需求和市場機會的評估

  • 概述
  • 加強對綜合分子檢測的教育,應用和改進
  • 對免疫療法的原發性和獲得性耐藥
  • 應對阻力的個性化方法
  • 可行的無突變治療選擇並改善患者預後

第9章管道評估

  • 概述
  • 有希望的藥物正在調查中

第10章,當前和將來的市場進入公司

  • 概述
  • 企業戰略趨勢
  • Merck & Co.
  • AstraZeneca
  • Roche
  • Eli Lilly
  • BMS
  • Pfizer
  • Boehringer Ingelheim
  • Novartis
  • 未來市場進入公司

第11章市場未來前景

  • 世界市場
    • 未來預測
    • 促進/抑制因素:國際問題
  • 5個主要歐洲國家(5EU)
    • 未來預測
    • 近年來的主要趨勢
    • 市場成長/抑制因素
  • 日本
  • 美國
  • 中國

第12章附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC211PIDR

Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women. Of total lung cancer incident cases, approximately 85% are the NSCLC subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis. Since the last global market forecast (2015-2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting. Although NSCLC is still not considered curable, physicians are enthusiastic about the progress being made in this field. New agents provide more durable responses, as demonstrated by improvements in progression-free survival and overall survival. Progress is demonstrated by the introduction of checkpoint inhibitors into the first-line setting and multiple next-generation targeted therapeutics which have dramatically improved patient outcomes.

These recent successes will be further built upon during the forecast period. Personalized medicine will become more precise, with the development of agents targeting niche molecular aberrations, currently underserved by available treatments. Furthermore, novel agents will allow targeting of new actionable mutations. The strategic use of these targeted agents and immuno-oncology (IO)-based therapies in effective combinatorial regimens in the neoadjuvant and adjuvant settings for specific patient populations is also expected to transform the treatment landscape over the forecast period.

GlobalData is expecting the entry of the introduction of 29 novel entrants over the forecast period of 2019-2029. In this report, GlobalData has weighed the clinical and commercial potential of each NSCLC therapy to forecast market growth and identify new commercial opportunities.

KEY QUESTIONS ANSWERED

  • 29 late-stage pipeline agents are going to enter the NSCLC market from 2019 onwards. Will the impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in NSCLC, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of 29 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
  • The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.
  • Among the late-stage pipeline products and marketed agents, Checkpoint inhibitors and EGFR inhibitors are expected to generate the greatest revenues over the forecast period.
  • The most important unmet needs in the NSCLC market include: Comprehensive molecular testing, novel approaches to primary and acquired resistance and an improvement in curative therapeutic options

Scope

  • Overview of NSCLC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline NSCLC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting NSCLC therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
  • Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global NSCLC therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 NSCLC: Executive Summary

  • 2.1 The NSCLC Market Will Expand to $32.9B in 2029
  • 2.2 Targeting Large Patient Populations in the First Line, with a Focus on Establishing New Actionable Mutations and Label Expansions for Premium Products into Earlier Lines
  • 2.3 Opportunities Remain for Tackling Primary and Acquired Resistance to Targeted and IO Based Therapies
  • 2.4 First-in-Class Approvals for Novel Actionable Mutations and Targeting Resistance
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
    • 5.4.3 Diagnosed Incident Cases of NSCLC
    • 5.4.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 5.4.5 Diagnosed Incident Cases of NSCLC by Histological Types
    • 5.4.6 Mutations Among Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma
    • 5.4.7 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 5.5 Epidemiological Forecast for NSCLC, 2019-2029
    • 5.5.1 Diagnosed Incident Cases of NSCLC
    • 5.5.2 Sex-Specific Diagnosed Incident Cases of NSCLC
    • 5.5.3 Age-Specific Diagnosed Incident Cases of NSCLC
    • 5.5.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 5.5.5 Diagnosed Incident Cases of NSCLC by Histological Type
    • 5.5.6 Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Mutations: Genomic Biomarkers, EGFR and KRAS Mutations
    • 5.5.7 Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations
    • 5.5.8 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 COVID-19 Impact
    • 5.6.3 Limitations of the Analysis
    • 5.6.4 Strengths of the Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan
  • 6.5 China

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Increased Education, Application, and Refinement of Comprehensive Molecular Testing
  • 8.3 Primary and Acquired Resistance to Immunotherapy
  • 8.4 Personalized Approaches to Tackling Resistance
  • 8.5 Improving Curative Options and Patient Outcomes for Those Without Actionable Mutations

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 Merck & Co.
  • 10.4 AstraZeneca
  • 10.5 Roche
  • 10.6 Eli Lilly
  • 10.7 BMS
  • 10.8 Pfizer
  • 10.9 Boehringer Ingelheim
  • 10.10 Novartis
  • 10.11 Future players

11 Market Outlook

  • 11.1 Global Markets
    • 11.1.1 Forecast
    • 11.1.2 Drivers and Barriers - Global Issues
  • 11.2 5EU
    • 11.2.1 Forecast
    • 11.2.2 Key Events
    • 11.2.3 Drivers and Barriers
  • 11.3 Japan
    • 11.3.1 Forecast
    • 11.3.2 Key Events
    • 11.3.3 Drivers and Barriers
  • 11.4 US
    • 11.4.1 Forecast
    • 11.4.2 Key Events
    • 11.4.3 Drivers and Barriers
  • 11.5 China
    • 11.5.1 Forecast
    • 11.5.2 Key Events
    • 11.5.3 Drivers and Barriers

12 Appendix

List of Tables

List of Tables

  • Table 1: NSCLC: Key Metrics in the 8MM
  • Table 2: Histologies and Subtypes in NSCLC
  • Table 3: TNM descriptors used in the AJCC/IASLC Lung Cancer Staging System
  • Table 4: Overview of the AJCC/IASLC staging system for NSCLC.
  • Table 5: Risk Factors and Comorbidities for NSCLC
  • Table 6: 8MM, Diagnosed Incident Cases of NSCLC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 7: 8MM, Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Immunotherapy and Genomic Biomarkers, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 8: 8MM, Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 9: Biomarker Testing Rates (%) in Nonsquamous NSCLC in 2019
  • Table 10: Treatment Guidelines for NSCLC in the 8MM
  • Table 11: Country Profile - US
  • Table 12: Country Profile - 5EU
  • Table 13: Country Profile - Japan
  • Table 14: Country Profile - China
  • Table 15: Leading Treatments for NSCLC, 2019
  • Table 16: Merck's NSCLC Portfolio Assessment, 2019
  • Table 17: AstraZeneca's NSCLC Portfolio Assessment, 2019
  • Table 18: Roche's NSCLC Portfolio Assessment, 2019
  • Table 19: Eli Lilly's NSCLC Portfolio Assessment, 2019
  • Table 20: BMS's NSCLC Portfolio Assessment, 2019
  • Table 21: Pfizer's NSCLC Portfolio Assessment, 2019
  • Table 22: Boehringer Ingelheim's NSCLC Portfolio Assessment, 2019
  • Table 23: Novartis' NSCLC Portfolio Assessment, 2019
  • Table 24: Future players in NSCLC Portfolio Assessment, 2019
  • Table 25: NSCLC Market - Global Drivers and Barriers, 2019-2029
  • Table 26: Key Events Impacting Sales for NSCLC in the 5EU, 2019-2029
  • Table 27: NSCLC Market - Drivers and Barriers in the 5EU, 2019-2029
  • Table 28: Key Events Impacting Sales for NSCLC in Japan, 2019-2029
  • Table 29: NSCLC Market - Global Drivers and Barriers in Japan, 2019-2029
  • Table 30: Key Events Impacting Sales for NSCLC in the US, 2019-2029
  • Table 31: NSCLC Market - Drivers and Barriers in the US, 2019-2029
  • Table 32: Key Events Impacting Sales for NSCLC in China, 2019-2029
  • Table 33: NSCLC Market - Global Drivers and Barriers in China, 2019-2029
  • Table 34: Key Historical and Projected Launch Dates for NSCLC
  • Table 35: Key Historical and Projected Patent Expiry Dates for NSCLC
  • Table 36: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for NSCLC in 2019 and 2029
  • Figure 2: Analysis of the Company Portfolio Gap in NSCLC During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of NSCLC During the Forecast Period
  • Figure 4: 8MM, Diagnosed Incidence of NSCLC, Men, Ages ≥18 Years, 2009-2029
  • Figure 5: 8MM, Diagnosed Incidence of NSCLC, Women, Ages ≥18 Years, 2009-2029
  • Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of NSCLC
  • Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
  • Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NSCLC by Histology Types
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma by PD-L1, TMB, EGFR, KRAS, BRAF V600E, and MET Exon 14 Mutations
  • Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Non-Squamous Cell Carcinoma Exon 18, Exon 19, Exon 20, Exon 21, KRAS G12C, KRAS G12D, KRAS G12V, ALK, BRAF, ROS1, RET, NTRK1, and HER2 Mutations
  • Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Squamous Cell Carcinoma by FGFR1, PIK3CA, DDR2, PTEN, ALK, ROS1, BRAF, and RET Mutations
  • Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of NSCLC
  • Figure 13: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, 2019
  • Figure 14: 8MM, Diagnosed Incident Cases of NSCLC, by Sex, Ages ≥18 Years, N, 2019
  • Figure 15: 8MM, Diagnosed Incident Cases of NSCLC by Age, Both Sexes, N, 2019
  • Figure 16: 8MM, Diagnosed Incident Cases of NSCLC by Histological Type, Ages ≥18 Years, Both Sexes, N, 2019
  • Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Ages ≥18 Years, Both Sexes, N, 2019
  • Figure 18: An Overview of the Treatment Algorithm in Non-invasive and Invasive NSCLC
  • Figure 19: The Current Paradigm for Biomarker-Driven Treatment in NSCLC
  • Figure 20: Unmet Needs and Opportunities in Non-small Cell Lung Cancer
  • Figure 21: Overview of the Development Pipeline in NSCLC
  • Figure 22: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to be Licensed for NSCLC in the 8MM During the Forecast Period
  • Figure 23: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of NSCLC During the Forecast Period
  • Figure 24: Analysis of the Company Portfolio Gap in NSCLC During the Forecast Period
  • Figure 25: Global (8MM) Sales Forecast by Country for NSCLC in 2019 and 2029
  • Figure 26: Sales Forecast by Class for NSCLC in the 5EU in 2019 and 2029
  • Figure 27: Sales Forecast by Class for NSCLC in Japan in 2019 and 2029
  • Figure 28: Sales Forecast by Class for NSCLC in the US in 2019 and 2029
  • Figure 29: Sales Forecast by Class for NSCLC in China in 2019 and 2029